Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 20878951 | HLA-A*24 | phosphate | NA | estramustine | NA | unclassified | |
| NA | |||||||
| 21090344 | HLA (HLA) | prostate cancer | NA | NA | NA | only_studied | |
| to investigate the clinical safety and effects of auto-dendritic cells pulsed with hla-a201-binding peptides prostate-specific antigen (psa) , prostate-specific membrane antigen (psma) and prostatic acid phosphatase (pap) in the treatment of hormone-refractory metastatic prostate cancer (hrpc). | |||||||
| 21253471 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| long-term follow-up of hla-a2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (psa146-154). | |||||||
| 21253471 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| twenty-eight hla-a2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, psa146-154, between july 2002 and september 2004 and monitored for clinical and immune responses. | |||||||
| 21350948 | HLA-A*02 | prostate cancer | NA | NA | NA | only_studied | |
| here, we evaluate the ar ligand-binding domain (lbd) as an immunological target, seeking to identify hla-a2-restricted epitopes recognized by t cells in prostate cancer patients. | |||||||
| 21350948 | HLA-A*02 | prostate cancer | NA | NA | NA | only_studied | |
| ten ar lbd-derived, hla-a2-binding peptides were identified and ranked with respect to hla-a2 affinity and were used to culture peptide-specific t cells from hla-a2+ prostate cancer patients. | |||||||
| 21350948 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| peptide-specific cd8+ t-cell clones were then isolated and characterized for prostate cancer cytotoxicity and cytokine expression, identifying that ar805 and ar811 cd8+ t-cell clones could lyse prostate cancer cells in an hla-a2-restricted fashion, but only ar811 ctl had polyfunctional cytokine expression. | |||||||
| 21350948 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| epitopes were confirmed using immunization studies in hla-a2 transgenic mice, in which the ar lbd is an autologous antigen with an identical protein sequence, which showed that mice immunized with ar811 developed peptide-specific ctl that lyse hla-a2+ prostate cancer cells. | |||||||
| 21350948 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| these data show that ar805 and ar811 are hla-a2-restricted epitopes for which ctl can be commonly detected in prostate cancer patients. | |||||||
| 21874303 | HLA-A*02 | prostate cancer | NA | NA | NA | only_studied | |
| we identified a naturally processed, hla-a*0201-restricted peptide epitope within the signal sequence region of klk4 that induced ctl responses in vitro in most healthy donors and prostate cancer patients tested. | |||||||
Copyright 2024